DP
VYGR icon

Diadema Partners’s Voyager Therapeutics VYGR Stock Holding History

Diadema Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Sell
413,642
-10,000
-2% -$37.9K 0.18% 93
2026
Q1 		$1.64M Buy
+423,642
New +$1.67M 0.28% 70

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Diadema Partners's VYGR Position: Q2 2026 in Review

Diadema Partners reduced its Voyager Therapeutics (VYGR) stake by 2.4% in Q2 2026, selling an estimated $37.9K and leaving 413,642 shares worth $1.45M. The position accounts for 0.18% of the portfolio, ranked #93.

Diadema Partners first reported a position in VYGR in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.64M in Q1 2026. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Diadema Partners held 413,642 shares of Voyager Therapeutics worth $1.45M as of Q2 2026.
  • Diadema Partners sold 10,000 Voyager Therapeutics shares in Q2 2026, an estimated $37.9K.
  • Voyager Therapeutics made up 0.18% of Diadema Partners's portfolio in Q2 2026, its #93 holding.
  • Diadema Partners first reported a position in Voyager Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Diadema Partners's Voyager Therapeutics position peaked at $1.64M in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.